The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via mu and kappa opioid receptors.

Clicks: 304
ID: 16771
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #18 of 36 articles by views in british journal of pharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Considerable effort has recently been directed at developing multifunctional opioid drugs to minimize the unwanted side-effects of opioid analgesics. We developed a novel multifunctional agonist named DN-9. Here, we studied the analgesic profiles and related side-effects of peripheral DN-9 in various pain models.Antinociceptive effects of DN-9 were investigated in nociceptive, inflammatory and neuropathic pain. Whole-cell patch-clamp and calcium imaging assays were used to evaluate the inhibitory effects of DN-9 to calcium current and high-K -induced intracellular calcium ([Ca ] ) on dorsal root ganglion (DRG) neurons, respectively. Furthermore, the side-effects of DN-9 were evaluated in antinociceptive tolerance, abuse, gastrointestinal transit and rotarod tests.Our study showed that subcutaneous DN-9 dose-dependently produced antinociception via peripheral opioid receptors in different pain models without sex difference. In addition, DN-9 exhibited more potent ability than morphine to inhibit calcium current and high-K -induced [Ca ] in DRG neurons. Repeated treatment with DN-9 produced equivalent antinociception for 8 days in multiple pain models, and DN-9 also maintained potent analgesia in morphine-tolerant mice. Furthermore, chronic DN-9 administration had no apparent effect on the microglial activation of spinal cord. DN-9 exhibited less abuse potential compared with morphine after subcutaneous injection, as was gastroparesis and effects on motor coordination.DN-9 produces potent analgesia with minimal side-effects, which strengthen the candidacy of peripherally acting opioids with multifunctional agonistic properties to enter human studies to alleviate the current highly problematic mis-use of classic opioid on a large scale.
Reference Key
xu2019thebritish Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Biao Xu, Mengna Zhang, Xuerui Shi, Run Zhang, Dan Chen, Yong Chen, Zilong Wang, Yu Qiu, Ting Zhang, Kangtai Xu, Xiaoyu Zhang, Wolfgang Liedtke, Rui Wang, Quan Fang
Are you one of these authors? Claim your profile
Journal british journal of pharmacology
Year 2019
DOI
10.1111/bph.14848
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.